(Q34590471)

3 August 2017

1 reference

title

Colon cancer prevention with NO-releasing NSAIDs (English)

1 reference

3 August 2017

1 reference

Chatargy S Kaza

1

1 reference

3 August 2017

Khosrow Kashfi

series ordinal

2

1 reference

3 August 2017

Basil Rigas

series ordinal

3

1 reference

3 August 2017

publication date

1 February 2002

1 reference

Prostaglandins and Other Lipid Mediators

3 August 2017

published in

1 reference

3 August 2017

volume

67

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

107-120

1 reference

3 August 2017

cites work

Cancer statistics, 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

In Vivo Antithrombotic Effects of a Nitric Oxide-Releasing Aspirin Derivative, NCX-4016

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Effect of single and repeated doses of a new nitroderivative of acetylsalicylic acid on platelet TXA2 production in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

A comparison of the anti-inflammatory and anti-nociceptive activity of nitroaspirin and aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Evidence that nitric oxide is an endogenous antiangiogenic mediator

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Inhibition of inducible nitric oxide synthase expression by novel nonsteroidal anti-inflammatory derivatives with gastrointestinal-sparing properties

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

The multifaceted roles of nitric oxide in cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0090-6980%2802%2900003-5

7 January 2021

10.1016/S0090-6980(02)00003-5

Identifiers

DOI

1 reference

3 August 2017

1 reference